Phreesia, Inc.

Informe acción NYSE:PHR

Capitalización de mercado: US$1.1b

Phreesia Dirección

Dirección controles de criterios 2/4

El CEO de Phreesia es Chaim Indig , nombrado en Jan 2005, tiene una permanencia de 19.83 años. compensación anual total es $8.27M, compuesta por 6% salario y 94% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.25% de las acciones de la empresa, por valor de $24.06M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 17.1 años, respectivamente.

Información clave

Chaim Indig

Chief Executive Officer (CEO)

US$8.3m

Compensación total

Porcentaje del salario del CEO6.0%
Permanencia del CEO19.8yrs
Participación del CEO2.2%
Permanencia media de la dirección3.8yrs
Promedio de permanencia en la Junta Directiva17.1yrs

Actualizaciones recientes de la dirección

Recent updates

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues

Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues

Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?

Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?

Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Phreesia: Remain Bullish Given The Healthy Growth Outlook

Sep 05

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve

Jun 06

The Price Is Right For Phreesia, Inc. (NYSE:PHR)

May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)

Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

May 03
Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Apr 12
At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Phreesia Continues To Stay Positive On The Business Growth

Apr 03

Phreesia: Healthcare Digitization Beneficiary Hampered By Valuation

Mar 01

Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Feb 16
Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Phreesia: Remain Buy Rated As The Business Pivot Towards Profitable Growth

Jan 04

Is Phreesia Finally Turning The Corner?

Dec 07

Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Oct 25
Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Phreesia: Share Price Dip Is A Buying Opportunity

Sep 21

Phreesia: Strong Execution Should Continue To Drive Growth

Jul 11

Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

May 18
Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

Phreesia: Strong Growth Momentum With Expanded TAM

Jan 28

Phreesia - Healthcare Ecosystem At An Attractive Valuation

Dec 13

Phreesia Q3 2023 Earnings Preview

Dec 07

Phreesia GAAP EPS of -$0.89 beats by $0.08, revenue of $67.9M beats by $2.15M

Sep 07

Phreesia: Their Time Has Passed

May 10

Opportunistic Time To Buy Phreesia's Healthcare Disruption

Dec 27

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chaim Indig en comparación con los beneficios de Phreesia?
FechaCompensación totalSalarioIngresos de la empresa
Jul 31 2024n/an/a

-US$100m

Apr 30 2024n/an/a

-US$119m

Jan 31 2024US$8mUS$495k

-US$137m

Oct 31 2023n/an/a

-US$144m

Jul 31 2023n/an/a

-US$152m

Apr 30 2023n/an/a

-US$162m

Jan 31 2023US$8mUS$515k

-US$176m

Oct 31 2022n/an/a

-US$185m

Jul 31 2022n/an/a

-US$181m

Apr 30 2022n/an/a

-US$158m

Jan 31 2022US$9mUS$515k

-US$118m

Oct 31 2021n/an/a

-US$80m

Jul 31 2021n/an/a

-US$50m

Apr 30 2021n/an/a

-US$32m

Jan 31 2021US$6mUS$419k

-US$27m

Oct 31 2020n/an/a

-US$23m

Jul 31 2020n/an/a

-US$19m

Apr 30 2020n/an/a

-US$83m

Jan 31 2020US$10mUS$346k

-US$91m

Oct 31 2019n/an/a

-US$102m

Jul 31 2019n/an/a

-US$113m

Apr 30 2019n/an/a

-US$54m

Jan 31 2019US$510kUS$300k

-US$45m

Compensación vs. Mercado: La compensación total de Chaim($USD8.27M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.21M).

Compensación vs. Ingresos: La compensación de Chaim ha aumentado mientras la empresa no es rentable.


CEO

Chaim Indig (44 yo)

19.8yrs

Permanencia

US$8,273,307

Compensación

Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Chaim Indig
Co-Founder19.8yrsUS$8.27m2.25%
$ 24.1m
Evan Roberts
Co-Founder & COO19.8yrsUS$4.50m1.3%
$ 14.0m
Balaji Gandhi
Chief Financial Officer1.7yrsUS$5.91m0.17%
$ 1.8m
Allison Hoffman
General Counsel & Secretary4.3yrsUS$3.04m0.082%
$ 877.5k
David Linetsky
Senior Vice President of Life Sciences5.7yrsUS$4.47m0.36%
$ 3.9m
Yvonne Hui
VP & Principal Accounting Officerless than a yearsin datossin datos
Jack Callahan
Chief Technology Officerless than a yearsin datossin datos
Maureen McKinney
Vice President of Corporate Communications3.8yrssin datossin datos
Ashwin Uttamchandani
Vice President of Sales & Marketing Operationsno datasin datossin datos
Amy VanDuyn
Senior Vice President of Human Resources14.6yrssin datos0.21%
$ 2.2m
Hilary Hatch
Chief Clinical Officer3.6yrssin datossin datos
Melissa Mitchell
Chief Privacy Officer1.4yrssin datossin datos

3.8yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PHR se considera experimentado (3.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Chaim Indig
Co-Founder19.8yrsUS$8.27m2.25%
$ 24.1m
Eve Kurtin
Board Observerno datasin datossin datos
Edward Cahill
Independent Director17.1yrsUS$232.46k0.065%
$ 696.3k
Michael Weintraub
Independent Chairman19.8yrsUS$384.98k0.57%
$ 6.2m
Richard Jackson
Member of Medical Advisory Boardno datasin datossin datos
Gillian Munson
Independent Director5.5yrsUS$257.46k0.018%
$ 189.2k
Elsa-Grace Giardina
Member of Medical Advisory Boardno datasin datossin datos
Mark Blais
Member of Medical Advisory Boardno datasin datossin datos
Michael Brodman
Member of Medical Advisory Boardno datasin datossin datos
Lee Schwamm
Member of Medical Advisory Boardno datasin datossin datos
Susan MacDonald
Member of Medical Advisory Boardno datasin datossin datos
Mark Smith
Independent Director6.1yrsUS$244.98k0.011%
$ 113.2k

17.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de PHR son experimentados ( 17.1 años antigüedad media).